Researchers look back at leukemia treatment results
NCT ID NCT03898128
Summary
This study collected information from 84 patients who had already received a targeted leukemia drug called anti-CD22 between 2014 and 2019. The goal was to learn more about how safe and effective the treatment was in everyday medical practice, outside of formal clinical trials. Researchers analyzed patient records to understand side effects, survival rates, and treatment costs, aiming to improve future care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AUSL Romagna
Ravenna, RA, 48121, Italy
-
Azienda ULSS2 Marca Trevigiana
Treviso, TV, 31100, Italy
-
Irst Irccs
Meldola (FC), FC, 47014, Italy
-
Ospedale S. Eugenio
Roma, 00144, Italy
-
ULSS 3 Serenissima
Mestre, Venezia, 30174, Italy
Conditions
Explore the condition pages connected to this study.